Finnhub•2026-04-20
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference CallGDRX — GoodRx Holdings Inc
NASDAQ · Health Care · Health Care
$2.37-12.55%Market cap702.28M
- Latest Close
- $2.37
- 30-Day Move
- -12.5%
- Market Cap
- $702M
- Shares Outstanding
- 342,570,000
- P/E Ratio
- 22.62
- P/B Ratio
- 1.49
NASDAQ:GDRXHealth Care / Health CareDelayed public snapshot
GoodRx Holdings Inc
A read-only Alphactor snapshot forGoodRx Holdings Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$2.37
30-Day Move
-12.5%
Market Cap
$702M
Shares Outstanding
342,570,000
P/E Ratio
22.62
P/B Ratio
1.49
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$2.37
-12.5%last 90 delayed daily bars
Market cap$702M
90D High
$2.96
90D Low
$1.77
Avg Volume
2,640,687
What stands out
Gross margin is running at 92.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 3.8%, useful for comparing GDRX against peers in Health Care.
GDRX is down 12.5% over the last 30 trading days shown on this page.
Latest operating income is $23M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$6.78
Rule of 40
12.4%
Dark Pool Short %
49.1%
Fundamentals snapshot
Latest Close
$2.37
30-Day Move
-12.5%
Market Cap
$702M
Shares Outstanding
342,570,000
P/E Ratio
22.62
P/B Ratio
1.49
ROE
4.9%
ROA
2.2%
Gross Margin
92.8%
Operating Margin
11.0%
Net Margin
3.8%
Debt / Equity
0.79
Current Ratio
2.61
Latest Revenue
$195M
Financial statement snapshot
Revenue
$195M
Gross Profit
$177M
Operating Income
$23M
Net Income
$5M
Gross Margin
9277.0%
Net Margin
382.0%
Current Ratio
2.61
Debt / Equity
0.79
Valuation snapshot
Fair Value
$6.78
Upside / Downside
+186.1%
Signal
Undervalued
Implied Growth
-1.5%
DCF
$2.75
EV/Rev
$10.81
Growth Assumption
1.3%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$94M
Valuation spread
Current Price
$2.37
Composite Fair Value
$6.78
DCF
$2.75
EV/Rev
$10.81
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Quality snapshot
Altman Z
0.24
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
5.52x
Rule of 40
12.4%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $767M | $2M | $-33M | $92M |
| 2023-12-31 | $750M | $-27M | $-9M | $83M |
| 2024-12-31 | $792M | $66M | $16M | $114M |
| 2025-12-31 | $797M | $87M | $30M | $94M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-15
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay MarketBenzinga•2026-04-15
GoodRx Says New Higher Dose Wegovy HD Injection 7.2 Mg Is Now Available To Eligible Self-Pay Patients On GoodRx At $399 Per MonthFinnhub•2026-04-15
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay PriceAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$178,434.55
Buys
0
Sells
5
Buy Value
$0
Sell Value
$178,434.55
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | Barnes Wendy Lynn | M | 110,963 | $0.00 |
| 2026-04-15 | Barnes Wendy Lynn | M | 51,177 | $0.00 |
| 2026-04-15 | Barnes Wendy Lynn | M | 115,148 | $0.00 |
| 2026-04-15 | Barnes Wendy Lynn | F | 48,203 | $2.23 |
| 2026-04-15 | Barnes Wendy Lynn | M | 110,963 | $0.00 |
| 2026-04-15 | Barnes Wendy Lynn | F | 22,232 | $2.23 |
| 2026-04-15 | Barnes Wendy Lynn | M | 51,177 | $0.00 |
| 2026-04-15 | Barnes Wendy Lynn | F | 50,021 | $2.23 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,732,761 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,157,280 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1,389,002 | 0.01% | 2025-12-31 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1,264,093 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,014,897 | 0.01% | 2025-12-31 |
| Pacer Funds Trust-Pacer US Small Cap Cash Cows 100 ETF | 779,542 | 0.01% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 686,679 | 0.01% | 2026-02-28 |
| Victory Portfolios II-VictoryShares Small Cap Free Cash Flow ETF | 537,329 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2025-08-11
$43M
-0.5%
Renaissance Technologies
Filed 2025-08-13
$18M
+19.5%
BlackRock
Filed 2024-08-13
$14M
--
Citadel Advisors
Filed 2025-08-14
$8M
--
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.